Home World News Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab... World News Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 256 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Mom Of Three Fought Breast Cancer, Drought, And Australia Bushfires In... January 8, 2020 How NatWest Group are making a difference this Giving Tuesday November 29, 2022 Study Finds That Gut Bacteria Could Be Used to Minimize Digestive... May 28, 2021 FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 Load more HOT NEWS Cancer in My Community: Improving Access to Palliative Care in Indonesia Easy Meals at Home Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays... FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction...
